Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 223-264-0 | CAS number: 3792-50-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in chemico
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 2017-04-11 to 2017-04-22
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
- Qualifier:
- according to guideline
- Guideline:
- other: Direct Peptide Reactivity Assay (DPRA) for Skin Sensitization Testing, DB-ALM Protocol n°154, January 12, 2013
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- direct peptide reactivity assay (DPRA)
Test material
- Reference substance name:
- Sodium hydrogen L-aspartate
- EC Number:
- 223-264-0
- EC Name:
- Sodium hydrogen L-aspartate
- Cas Number:
- 3792-50-5
- Molecular formula:
- C4H7NO4.Na
- IUPAC Name:
- sodium hydrogen 2-aminosuccinate
- Test material form:
- solid
Constituent 1
In chemico test system
- Details on the study design:
- Skin sensitisation (In chemico test system)
- Details on study design: The in chemico direct peptide reactivity assay (DPRA) enables detection of the sensitising potential of a test item by quantifying the reactivity of test chemicals towards synthetic peptides containing either lysine or cysteine.
Results and discussion
- Positive control results:
- The 100 mM stock solution of the positive control (cinnamic aldehyde) showed high reactivity towards the synthetic peptides.
The mean peptide depletion of the positive control for the cysteine peptide was between 60.8 % and 100 % (74.90 %).
The mean peptide depletion of the positive control for the lysine peptide was between 40.2 % and 69.0 % (54.93 %).
In vitro / in chemico
Resultsopen allclose all
- Key result
- Run / experiment:
- other: cysteine run
- Parameter:
- other: mean peptide depletion [%]
- Value:
- 0.57
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Run / experiment:
- other: lysine run
- Parameter:
- other: mean peptide depletion [%]
- Value:
- 0.42
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Other effects / acceptance of results:
- ACCEPTANCE OF RESULTS:
- Acceptance criteria met for negative control: Yes
- Acceptance criteria met for positive control: Yes
- Acceptance criteria met for variability between replicate measurements: Yes
Any other information on results incl. tables
Cysteine and Lysine Values of the Calibration Curve
Sample |
Cysteine Peptide |
Lysine Peptide |
||
Peak Area |
Peptide Concentration [mM] |
Peak Area |
Peptide Concentration [mM] |
|
STD7 |
0.0000 |
0.0000 |
0.0000 |
0.0000 |
STD6 |
153.8068 |
0.0167 |
139.6547 |
0.0167 |
STD5 |
321.6256 |
0.0334 |
281.4845 |
0.0334 |
STD4 |
642.2243 |
0.0667 |
555.3300 |
0.0667 |
STD3 |
1318.5444 |
0.1335 |
1100.1805 |
0.1335 |
STD2 |
2593.4377 |
0.2670 |
2176.1533 |
0.2670 |
STD1 |
5075.1016 |
0.5340 |
4280.0898 |
0.5340 |
Depletion of the Cysteine Peptide
Cysteine Peptide |
||||||
Sample |
Peak Area at 220 nm |
Peptide Concentration [mM] |
Peptide Depletion [%] |
Mean Peptide Depletion [%] |
SD of Peptide Depletion [%] |
CV of Peptide Depletion [%] |
Positive Control |
1193.1283 |
0.1239 |
74.99 |
74.90 |
0.25 |
0.34 |
1187.7434 |
0.1233 |
75.10 |
||||
1210.7732 |
0.1258 |
74.62 |
||||
Test Item |
4777.8320 |
0.5002 |
0.00* |
0.57 |
0.52 |
91.06 |
4674.7964 |
0.4893 |
1.01 |
||||
4689.8892 |
0.4909 |
0.69 |
* value set to zero due to negative depletion
Depletion of the Lysine Peptide
Lysine Peptide |
||||||
Sample |
Peak Area at 220 nm |
Peptide Concentration [mM] |
Peptide Depletion [%] |
Mean Peptide Depletion [%] |
SD of Peptide Depletion [%] |
CV of Peptide Depletion [%] |
Positive Control |
1861.8433 |
0.2304 |
55.78 |
54.93 |
0.78 |
1.42 |
1926.2322 |
0.2384 |
54.25 |
||||
1904.2300 |
0.2357 |
54.77 |
||||
Test Item |
4143.4482 |
0.5151 |
0.80 |
0.27 |
0.46 |
173.21 |
4257.1900 |
0.5293 |
0.00* |
||||
4338.8200 |
0.5395 |
0.00* |
* values set to zero due to negative depletion
Prediction Model 1
Cysteine 1:10/ Lysine 1:50 Prediction Model1
Mean Cysteine andLysine PPD |
ReactivityClass |
DPRA Prediction² |
0.00 % ≤ PPD ≤ 6.38% |
No or Minimal Reactivity |
Negative |
6.38 % < PPD ≤ 22.62% |
Low Reactivity |
Positive |
22.62 % < PPD ≤ 42.47% |
Moderate Reactivity |
|
42.47 % < PPD ≤ 100% |
High Reactivity |
1 The numbers refer to statistically generated threshold values and are not related to the precision of the measurement.
2 DPRA predictions should be considered in the framework of an IATA.
Prediction Model 2
Cysteine 1:10 prediction model1
Cysteine PPD |
ReactivityClass |
DPRA Prediction² |
0.00% ≤ PPD ≤ 13.89 % |
No orMinimalReactivity |
Negative |
13.89% < PPD ≤ 23.09 % |
LowReactivity |
Positive |
23.09% < PPD ≤ 98.24 % |
ModerateReactivity |
|
98.24% < PPD ≤ 100 % |
High Reactivity |
1 The numbers refer to statistically generated threshold values and are not related to the precision of the measurement.
2 DPRA predictions should be considered in the framework of anIATA.
Categorization of the Test Item
Prediction Model |
Prediction Model 1 (Cysteine Peptide and Lysine Peptide / Item Ratio: 1:10 and 1:50) |
Prediction Model 2 (Cysteine Peptide / Test Item Ratio: 1:10) |
||||
Test Substance |
Mean Peptide Depletion [%] |
Reactivity Category |
Prediction |
Mean Peptide Depletion [%] |
Reactivity Category |
Prediction |
Test Item |
0.42 |
Minimal Reactivity |
no sensitizer |
0.57 |
Minimal Reactivity |
no sensitizer |
Positive Control |
64.92 |
High Reactivity |
sensitizer |
74.90 |
Moderate Reactivity |
sensitizer |
Applicant's summary and conclusion
- Interpretation of results:
- other: In this study the test item showed minimal reactivity towards the peptides. The test item can be classified as “non-sensitiser”.
- Remarks:
- The data generated with this method may be not sufficient to conclude on the absence of skin sensitisation potential of chemicals and should be considered in the context of integrated approach such as IATA.
- Conclusions:
- In an in vitro direct peptide reactivity assay (DPBA) according to OECD Guideline 442C, the test substance showed a cystein depletion of 0.57 % and a lysine depletion of 0.42 %, indicating no sensitising properties.
- Executive summary:
In an in vitro direct peptide reactivity assay according to OECD Guideline 442C, the sensitising potential of L-Aspartic acid sodium salt monohydrate was determined (reference 7.4.1 -1) The test item solutions were tested by incubating the samples with the peptides containing either cysteine or lysine for 24 ± 2 h at 25 ± 2.5 °C. Subsequently samples were analysed by HPLC. For the 100 mM stock solution of the test item no turbidity or precipitation was observed when diluted with the cysteine peptide solution. After the 24 h ± 2 h incubation period but prior to the HPLC analysis samples of the cysteine peptide run were inspected for precipitation, turbidity or phase separation. No precipitation, turbidity or phase separation was observed for the test item samples. A slight precipitation was observed for standard 1 and the positive control samples. Since the acceptance criteria for the linearity of the standard curve as well as for the depletion range of the positive control were fulfilled, the observed precipitations were regarded as insignificant.
For the 100 mM stock solution of the test item no turbidity or precipitation was observed when diluted with the lysine peptide solution. After the 24 h ± 2 h incubation period but prior to the HPLC analysis samples of the lysine peptide run were inspected for precipitation, turbidity or phase separation. No precipitation, turbidity or phase separation was observed for any sample.
No co-elution of test item with the peptide peaks was observed. Sensitizing potential of the test item was predicted from the mean peptide depletion of both peptides by comparing the peptide concentration of the test item samples to the corresponding reference control C.
In the lysine run a shift of the lysine peptide peak from 7.7 min to 7.0 up to 6.5 min was observed. Since the reference control samples allow clear identification of the lysine peptide and since the test item did not elute between 6.5 and 7.7 min, that indeed the lysine peptide peak had shifted and that the peak area of that peak did only represent remaining lysine peptide. Furthermore, all validity criteria were fulfilled, and this shift was not considered having an influence on the quality or validity of the results. The 100 mM stock solution of the test item showed minimal reactivity towards the synthetic peptides. The mean depletion of both peptides was ≤ 6.38 % (0.42 %). Based on the prediction model 1 the test item can be considered as non-sensitiser. The 100 mM stock solution of the positive control (cinnamic aldehyde) showed high reactivity towards the synthetic peptides. The mean depletion of both peptides was 64.92 %.
Based on these results, the test substance was considered as non-sensitising.
Furthermore, it was assumed, that the anhydrate form has the same sensitising potential and thus the result of the test item is also applicable.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.